(NASDAQ: IMUX) Immunic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.82%.
Immunic's earnings in 2026 is -$104,287,000.On average, 11 Wall Street analysts forecast IMUX's earnings for 2026 to be -$57,969,128, with the lowest IMUX earnings forecast at -$93,710,650, and the highest IMUX earnings forecast at -$35,756,506. On average, 10 Wall Street analysts forecast IMUX's earnings for 2027 to be -$44,843,426, with the lowest IMUX earnings forecast at -$120,809,314, and the highest IMUX earnings forecast at -$8,581,561.
In 2028, IMUX is forecast to generate -$45,641,647 in earnings, with the lowest earnings forecast at -$78,492,681 and the highest earnings forecast at -$22,169,034.